A Study to Determine the Effects of MK0557 in Obese Subjects

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
First received: September 19, 2007
Last updated: September 20, 2007
Last verified: September 2007

The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.

Condition Intervention Phase
Drug: MK0557
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Study Start Date: December 2003
Study Completion Date: December 2003

Ages Eligible for Study:   21 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women between 21 and 65 years of age, willing to avoid all prescription and nonprescription medicine to alter body weight for entire study

Exclusion Criteria:

  • You are or plan to become pregnant
  • You have smoked or used nicotine within 6 months of the study
  • History of abusing alcohol and/or drugs
  • History of a stroke, you have diabetes mellitus, you are taking medication for high blood pressure, you have had recent surgery, you have been involved in another study within 3 months of study, use of cholesterol or anti-seizure medication during the study
  • Have participated in a weight loss program 3 months before the study or during the course of the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00533598

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00533598     History of Changes
Other Study ID Numbers: 2007_613
Study First Received: September 19, 2007
Last Updated: September 20, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on April 17, 2014